Drug Trial Radar · NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Jan 30, 2025
Primary completion
May 20, 2030
Study completion May 20, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
Conditions
- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Mantle-cell Lymphoma
- Large B-cell Lymphoma
- B-cell Non-Hodgkin Lymphoma
Interventions
SurovatamigDrug
Surovatamig will be administered as either SC injection or IV infusion.
Prednisone (or equivalent)Drug
Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.
RituximabDrug
Rituximab will be administered as IV infusion as per standard of care.
CyclophosphamideDrug
Cyclophosphamide will be administered as IV infusion as per standard of care.
VincristineDrug
Vincristine will be administered as IV infusion as per standard of care.
DoxorubicinDrug
Doxorubicin will be administered as IV infusion as per standard of care.
AcalabrutinibDrug
Acalabrutinib will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special InterestTime frame: Up to 6 years 4 months
- Number of Participants with Dose Limiting Toxicity (DLTs)Time frame: Up to 2 months
Locations
66 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Boston, Massachusetts · Recruiting
Research Site
Hackensack, New Jersey · Recruiting
Research Site
New Brunswick, New Jersey · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
Charlotte, North Carolina · Recruiting
Research Site
Charlotte, North Carolina · Not yet recruiting
Research Site
Winston-Salem, North Carolina · Not yet recruiting
Research Site
Columbus, Ohio · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Heidelberg, Australia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Jinan, China · Withdrawn
Research Site
Tianjin, China · Recruiting
Research Site
Zhengzhou, China · Recruiting
Research Site
Ostrava - Poruba, Czechia · Recruiting
Research Site
Prague, Czechia · Recruiting
Research Site
Praha 2 - Nové Město, Czechia · Recruiting
Research Site
Aalborg, Denmark · Recruiting
Research Site
Aarhus N, Denmark · Recruiting
Research Site
Copenhagen, Denmark · Recruiting
Research Site
Odense C, Denmark · Recruiting
Research Site
Clermont-Ferrand, France · Recruiting
Research Site
Montpellier, France · Recruiting
Research Site
Paris, France · Recruiting
Research Site
Saint-Cloud, France · Recruiting
Research Site
Villejuif, France · Recruiting
Research Site
Cologne, Germany · Recruiting
Research Site
Homburg, Germany · Not yet recruiting
Research Site
Kiel, Germany · Recruiting
Research Site
Mainz, Germany · Not yet recruiting
Research Site
München, Germany · Recruiting
Research Site
Würzburg, Germany · Recruiting
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.